Compare ARBE & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBE | BMEA |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Israel | United States |
| Employees | 144 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 91.1M |
| IPO Year | N/A | 2021 |
| Metric | ARBE | BMEA |
|---|---|---|
| Price | $0.70 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.38 | ★ $9.83 |
| AVG Volume (30 Days) | ★ 1.4M | 636.9K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $363.94 | N/A |
| Revenue Next Year | $286.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.87 |
| 52 Week High | $2.88 | $2.99 |
| Indicator | ARBE | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 39.14 |
| Support Level | $0.65 | $1.05 |
| Resistance Level | $0.90 | $1.44 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 39.33 | 30.23 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.